Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-10, Vol.385 (15), p.1393-1400
Hauptverfasser:	Bar-On, Yinon M, Goldberg, Yair, Mandel, Micha, Bodenheimer, Omri, Freedman, Laurence, Kalkstein, Nir, Mizrahi, Barak, Alroy-Preis, Sharon, Ash, Nachman, Milo, Ron, Huppert, Amit
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Coronavirus Coronaviruses COVID-19 COVID-19 vaccines Disease transmission General & Internal Medicine Generalized linear models Illnesses Infections Infectious Disease Injection Life Sciences & Biomedicine Medicine, General & Internal mRNA Original Population Science & Technology Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of 11.3, and the rate of severe illness was lower by a factor of 19.5.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2114255